Oncology development

The Scan Is Only Part of the Story: Making Oncology PRO Data Usable

Understand how patient-reported outcomes complement tumor measures, and what site teams need for reliable collection.

By Lampgen Clinical Research

A patient journal and house key in focus with a blurred radiology display behind, illustrating daily experience alongside imaging.
Conceptual editorial illustration; it does not depict an observed study procedure, actual patient data or a demonstrated treatment outcome.

3 min read · estimated

Sources
Tumor outcomeDaily experience
Complementary evidence; missing responses do not reveal their own cause.

What the source reported

FDA’s October 2024 guidance recommends collecting core patient-reported concepts including disease symptoms, symptomatic adverse events, overall side-effect impact, physical function and role function. It addresses instrument selection and trial design. [1] FDA’s October 15, 2026 workshop agenda explored measurement gaps associated with newer therapies, longer survivorship, patient co-design and more frequent assessment. [2] A workshop agenda is not a new binding requirement or evidence that a particular collection strategy improves outcomes.

What this means for trial teams

Lampgen’s analysis: tumor measurements and the patient’s account answer related but different questions. A trial can document disease response while still needing better evidence about how treatment affects daily activities. Collecting that perspective well requires deliberate design and dependable execution, rather than adding a questionnaire to an already crowded visit.

Begin with the reason for each assessment. The study team should understand what the instrument measures, when the response is intended to represent the patient’s experience and how it fits the visit schedule. The approved instrument, protocol and analysis plan determine the specific approach. Convenience should not silently change the meaning of a measurement.

At the site, establish a collection workflow. Identify who introduces the assessment, checks access and supports technical problems without coaching answers. Confirm that participants understand the permitted method and language. If a device or connection fails, follow the study’s contingency process rather than creating a substitute that may change how responses are collected.

Training should make role boundaries explicit. Staff can explain the approved procedure and address access barriers while preserving the participant’s own account. They should also know the separate clinical contact and safety-reporting pathways. Completing a questionnaire is not necessarily a substitute for reporting an urgent symptom, and a research platform should not be presented as continuously monitored unless that service is actually established.

Missing data deserves investigation. Review when assessments are absent, which sites or visit periods show a pattern and what reasons have been recorded. Technical problems, scheduling and illness are possible explanations, but the missing response itself proves none of them. Avoid retrospective guesses that turn an unknown experience into apparently complete data.

For CTMs, include PRO delivery in the operational conversation with data management, clinical colleagues, vendors and site staff. Ask whether the planned collection frequency is feasible, how exceptions are documented and who resolves repeated access problems. Consider the participant’s burden alongside the information each assessment is meant to provide. More frequent measurement is not automatically more useful measurement.

The patient impact depends on what the study can actually learn and how that information informs decisions. Reliable PRO evidence can enrich interpretation of benefit and burden; it does not make a regimen effective or establish an individual treatment recommendation. The objective is an honest account of experience alongside the other endpoints.

Lampgen’s staffing perspective is to look for professionals who understand why assessment timing, participant communication and source traceability matter. A usable patient voice requires a workflow that allows the patient to provide it.

Sources

  1. FDA — Core Patient-Reported Outcomes in Cancer Trials, October 2024
  2. FDA — 11th Annual COA Cancer Clinical Trials Workshop, October 15, 2026

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?